Suggested citation for this article: Kelling SE, Rondon-Begazo A, DiPietro Mager NA, Murphy BL, Bright DR. Provision of Clinical Preventive Services by Community Pharmacists. Prev Chronic Dis 2016;13:160232. DOI: http://dx.doi.org/10.5888/pcd13.160232.
Through providing select examples of community pharmacists implementing USPSTF A and B recommendations, we hope that more public health and health care professionals will realize the potential of pharmacists to expand access to clinical preventive services and that additional ideas for collaboration will be stimulated.

Methods

All 95 USPSTF recommendations were reviewed in March 2015, and those that were rated A or B and that focused on services for nonpregnant adults were considered for inclusion in the study. We searched PubMed using the key word “community pharmacy” and key words from the US Preventive Services Task Force recommendations rated A or B to identify studies demonstrating implementation of clinical preventive services by community pharmacists in the United States. Based on the expertise of the authors and a review of published literature, recommendations were categorized as either opportunities for community pharmacists to conduct the service within pharmacies or to provide education and outside referral.

From the published literature that was identified, we selected articles that represented various services across different types of community pharmacies. The intention of the article selection process was not to create an exhaustive listing or review of service models but to provide a diverse representation of services in the literature to spur discussion and thought about how to further incorporate pharmacists into preventive care. Because the USPSTF does not make its own recommendations about vaccinations and a substantial literature already documenting pharmacist impact exists in this area, articles focused on pharmacist provision of vaccinations were excluded from review.

Of the 95 USPSTF recommendations reviewed, 32 were rated as A or B recommendations and focused on nonpregnant adults (Figure). A total of 18 recommendations were categorized as opportunities for community pharmacists to conduct the service (Table 1) and 14 recommendations were categorized as opportunities for community pharmacists to provide education or referrals (Table 2). Pharmacist implementation of interventions that were focused on folic acid education, tobacco use cessation, osteoporosis screening, and HIV screening were selected for discussion here.

Primary Prevention

Preventive medication: folic acid supplementation

Community pharmacists are well-situated to counsel women of childbearing potential about folic acid for the prevention of neural tube defects (NTDs). Although NTDs affect approximately 3,000 pregnancies each year in the United States, 50% to 70% of NTDs are preventable by consuming adequate amounts of folic acid daily before conception and during the first trimester of pregnancy (8,9). Because many women do not consume the necessary amounts of folic acid through diet alone and there is a high rate of unplanned pregnancies in the United States, supplementation in the form of a folic acid tablet or multivitamin containing folic acid is recommended for all women of childbearing potential, regardless of pregnancy intention (1). For most women of childbearing potential, 400 μg (0.4 mg) is the recommended daily dose. Women with certain risk factors should be advised to take higher doses, including women with diabetes (usually 4–5 mg/d), using anti-epileptic drugs (usually 4 mg/d), or who have experienced a previous NTD-affected pregnancy (usually 4 mg/d) (10).

Many American women are still not aware of the need for daily folic acid intake to prevent NTDs (11). In addition, data indicate that health care professionals are not consistently informing women about this need (11). However, nearly 90% of women responding to a March of Dimes survey indicated that they would be likely to take a daily folic acid supplement if advised to do so by a health care provider (11).
There are many ways that community pharmacists can fill these unmet needs. Education interventions, such as a live educational program led by pharmacists and student pharmacists result in statistically significant improvements in knowledge and increased use of folic acid by participants (12–14). In addition, recommendations for folic acid can be addressed through medication therapy management (10). Finally, pharmacists can use promotional materials such as posters and brochures in their pharmacies to raise awareness about folic acid and initiate conversations with patients. National observances each January for National Birth Defects Prevention Month and Folic Acid Awareness Week and in March for World Birth Defects Day provide further opportunities to promote folic acid use among patients in the community pharmacy.

Secondary Prevention

Healthy behaviors: tobacco use

The USPSTF recommends that all adults be asked about tobacco use and be provided cessation interventions if they use tobacco products (1). The 2014 National Health Interview Survey (NHIS) reported a significant reduction in tobacco smoking from 20.9% (45.1 million people) in 2005 to 16.8% (40.0 million people) in 2014 (15). Proven population-based interventions (tobacco price increases, smoke-free laws, media campaigns, increased access to smoking cessation programs) are producing positive outcomes; however, the Healthy People 2020 objective is to reduce the prevalence of tobacco smoking to less than 12% (15). Among the surveyed individuals in the NHIS, people who live below the federal poverty level, have a General Educational Development (GED) certification, are racial/ethnic minorities, are nonstraight adults, are uninsured, and have only Medicaid had a high smoking prevalence. Community pharmacists are uniquely positioned to assist in attaining the Healthy People 2020 objective because of their training and their accessibility to vulnerable populations. Furthermore, engagement of multiple health professionals increases readiness to quit smoking, and studies have demonstrated success in the community pharmacy setting (16).

Common barriers to providing tobacco use cessation services in community pharmacies include time limitations, lack of training, and pharmacist self-efficacy. The Ask, Advise, Refer (AAR) model (17) addresses the time barrier. It requires less than 5 minutes and allows for prompt and short interventions with the assistance of pharmacy technicians. Patwardhan and Chewning randomly assigned 16 high-volume chain pharmacies to either the intervention (use of AAR, tobacco use cessation posters, and pharmacy technician involvement in the Ask and Fax-to-Quit enrollment steps) or control (provide quitline cards only) groups (17). A significantly higher number of patients in the intervention groups were asked about tobacco use, advised to quit, and enrolled in the quitline.

Frameworks such as the AAR, AAC (Ask, Advice, Connect), and the 5 A’s (Ask, Advise, Assess, Assist, Arrange) provide feasible means for community pharmacists to assist patients in tobacco use cessation (17).

Chronic disease screening: osteoporosis

The USPSTF recommends that women aged 65 years or older, as well as younger women at a high risk of fractures, be screened for osteoporosis (1). There are many risk factors for osteoporosis, and the FRAX tool (https://www.shef.ac.uk/FRAX/) can be used to assess an individual’s 10-year risk of osteoporotic fracture based on age, sex, presence of rheumatoid arthritis or secondary causes of osteoporosis, fracture history, family history of fracture, bone mineral density, smoking status, body mass index, alcohol use, and glucocorticoid use. Because osteoporosis is an asymptomatic disease that affects more than 10.2 million Americans (29) and can lead to fractures resulting in substantial illnesses and deaths, screening services are important for early identification of this bone abnormality to ensure provision of appropriate treatment and reduction in fracture risk.

Although dual-energy X-ray absorptiometry (DXA) remains the gold standard for diagnosing osteoporosis, quantitative ultrasonography (QUS) provides a less expensive, more readily accessible alternative for initial screening of individuals (1). Although it cannot be used to diagnose osteoporosis, QUS of the calcaneus allows for prediction of fracture risk of the femoral neck, hip, and spine, and is frequently used to identify people who should receive follow-up screening with DXA for potential diagnosis (1).

Because of its portability, comparatively low cost, and ease of use, QUS provides pharmacists in the community setting an opportunity to improve rates of screening for osteoporosis. Several models have been published that illustrate community pharmacists screening patients for osteoporosis (18–20). In some, patients self-identified the need for screening based on perceived risk; other involved referrals by physicians from various clinical settings (19–21).

Infectious disease screening: HIV

The opportunity to screen for chronic infectious diseases, such as HIV, has been demonstrated in community pharmacies (22). Approximately 240,000 people with HIV in the United States are undiagnosed (23). Early diagnosis may lead to early treatment and reduced disease spread. Testing can be conducted at community pharmacies to increase access to care (22–24).
The Centers for Disease Control and Prevention completed a pilot in which confidential HIV testing was offered at 21 sites across the United States, including 18 community pharmacies (24). Community pharmacies can serve as a HIV testing sites with specific care linkages for referral for confirmatory testing and clinical support (23). When this service was implemented in 2 community pharmacies in Michigan, there was a similar testing rate (1.5%) (22). That study also found that the pharmacist felt comfortable performing the testing.

The Food and Drug Administration approved the first oral HIV home test kit that can be purchased in pharmacies across the country (25). Pharmacists interviewed in one study suggested that consultation and counseling would be helpful when the over-the-counter HIV test is purchased (eg, discussion of test procedure, building a relationship so that future consultation could occur if desired) (25). Community pharmacists can also provide appropriate counseling related to disease education and prevention strategies (eg, safe sex strategies, injection and syringe habits).

Counseling and Referral

Community pharmacists are well suited to provide education and referrals for community members in need of clinical preventive services that are not routinely offered at pharmacies or that pharmacists usually do not perform. These services could include screenings that the pharmacy chooses not to provide (eg, not cost-effective, the pharmacy staff are not trained to provide) or screenings that are not feasible in the community pharmacy setting (eg, screenings requiring specialized equipment or expertise). Pharmacists can identify patients who are candidates for specific screenings, provide education to the patient, and if appropriate make a recommendation about where to receive the screening. Examples of USPSTF recommendations that community pharmacists could provide education and referrals for may include screenings for abdominal aortic aneurysms, BRCA genetic testing, colorectal cancer, and depression.

Discussion

Community pharmacists are increasingly being recognized as potential partners in many public health activities. Pharmacists have demonstrated their utility in many areas, including chronic disease management (6,7). Similarly, community pharmacists can improve population health through the provision of clinical preventive services. To expand population coverage for clinical preventive services, public health and health care professionals should consider including community pharmacies because of their expertise and unique accessibility. Community pharmacies offer convenient hours and locations for millions of Americans and, as a result, can provide critical access to these services for vulnerable populations and those considered hard to reach (8). The development of clinical–community linkages, whereby public and private sectors collaborate, helps to increase patient access to various services by increasing coordination of services, identifying and closing gaps in services, and encouraging community members to become involved in improvement initiatives (26).

Community pharmacists who provide clinical preventive services often need to build collaborative partnerships with other health care professionals. Depending on the state’s laws, pharmacists may be able to provide clinical preventive services directly to patients without direct oversight of a physician or other health care professional. However, developing partnerships helps to ensure that patients who are identified as having high risk (eg, positive depression screening) have access to appropriate follow-up services (eg, cognitive behavioral therapy, pharmacotherapy). In some situations, it may be helpful for the community pharmacy to have a collaborative practice agreement, which would allow an expanded scope of practice. Although state laws vary, in general a collaborative practice agreement may authorize pharmacists to order laboratory testing, to start or change drug therapy, or to do other duties through formal collaboration with a prescriber. Furthermore, health care professionals may find value in referring their patients to pharmacy-based services, particularly those services which are time consuming (eg, healthy diet and physical activity counseling). Strategies that also may help to create partnerships include meeting face-to-face to develop rapport between the different health care professionals and working toward a shared electronic health record to effectively communicate about patient care (27,28). Pharmacists may be able to be reimbursed for these services directly or indirectly, given their practice site and scope of practice.

Conclusion

Clinical preventive services offer the opportunity to improve the health of populations and decrease health care costs. Community pharmacists have demonstrated the ability to implement USPSTF recommendations, either through screening, education, and recommendations to patients (eg, folic acid supplementation, tobacco use cessation) or screening and referrals to primary care providers for follow up testing and care (eg, osteoporosis screening, HIV screening). We provide a summary of services that community pharmacists can offer as well as selected examples of interventions addressing USPSTF A and B recommendations. As part of interdisciplinary teams and clinical–community links, community pharmacists can improve population health through provision of clinical preventive services.
Acknowledgments

Jeffrey A. Bates, PharmD, CGP, Cedarville University.

Author Information

Corresponding Author: Sarah E. Kelling, PharmD, MPH, Clinical Assistant Professor, Clinical Pharmacy, University of Michigan College of Pharmacy, 428 Church St, Ann Arbor, MI 48104. Telephone: 734-763-6691. Email: skelling@med.umich.edu.

Author Affiliations: Angela Rondon-Begazo, University of Michigan College of Pharmacy, 428 Church St, Ann Arbor, MI 48104. Assistant Professor, Clinical Pharmacy, University of Michigan College of Pharmacy, 428 Church St, Ann Arbor, MI 48104. Author Information

References

1. United States Preventive Services Task Force. Recommendations for primary care practice. http://www.uspreventiveservicestaskforce.org/Page/Name/recommendations. Accessed September 20, 2016.

2. Partnership for Prevention. Preventive care: a national profile on use, disparities, and health benefits. http://www.rwjf.org/content/dam/farm/reports/reports/2007/rwjf13325. Accessed September 20, 2016.

3. Fox JB, Shaw FE. Receipt of selected clinical preventive services by adults — United States, 2011–2012. MMWR Morb Mortal Wkly Rep 2015;64(27):738–42.

4. Healthcare.gov. Preventive health services. https://www.healthcare.gov/coverage/preventive-care-benefits/. Accessed September 20, 2016.

5. Giberson S, Yoder S, Lee MP. Improving patient and health system outcomes through advanced pharmacy practice: a report to the U.S. Surgeon General. 2011. http://www.accp.com/docs/positions/misc/improving_patient_and_health_system_outcomes.pdf. Accessed September 20, 2016.

6. Morrison CM, Glover D, Gilchrist SM, Casey MO, Lanza A, Lane RI, et al. A program guide for public health: partnering with pharmacists in the prevention and control of chronic diseases. National Center for Chronic Disease Prevention and Health Promotion. http://www.cdc.gov/ndphsp/programs/spha/docs/pharmacist_guide.pdf. Accessed September 20, 2016.

7. National Association of Chain Drug Stores. Re: health care workshop, project no. P131207. http://www.nacds.org/ceo/2014/0508/supplemental_comments.pdf. Accessed September 20, 2016.

8. Division of Birth Defects, National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention. Birth Defects COUNT: countries and organizations united for neural tube defects prevention. http://www.cdc.gov/ncbddd/folicacid/global.html. Accessed September 20, 2016.

9. Centers for Disease Control and Prevention. Recommendations for the use of folic acid to reduce the number of cases of spina bifida and other neural tube defects. MMWR Recomm Rep 1992;41(RR-14):1–7.

10. DiPietro NA, Bright DB. Medication therapy management and preconception care: opportunities for pharmacist intervention. Inov Pharm 2014;5(1):141.

11. Gallup and March of Dimes Foundation. Improving preconception health: women’s knowledge and use of folic acid. https://www.marchofdimes.org/peristats/pdfdocs/2008FolicAcidSurveyReport.pdf. Accessed September 20, 2016.

12. DiPietro NA, Kier KL. An educational intervention about folic acid and healthy pregnancies targeted at college-age women. J Am Pharm Assoc (Wash) 2001;41(2):283–5.

13. Murphy BL, DiPietro NA, Kier KL. Knowledge and use of folic acid among college women: a pilot health promotion program led by pharmacy students and faculty. Pharm Pract (Granada) 2010;8(4):220–5.

14. Murphy BL, DiPietro NA. Impact of a pharmacist-directed educational program on the long-term knowledge and use of folic acid among college women: a 12-month follow-up study. Pharm Pract (Granada) 2012;10(2):105–9.

15. Jamal A, Homa DM, O’Connor E, Babb SD, Caraballo RS, Singh T, et al. Current cigarette smoking among adults — United States, 2005–2014. MMWR Morb Mortal Wkly Rep 2015;64(44):1233–40. https://www.cdc.gov/mmwr/preview/mmwrhtml/mm6444a2.htm.

16. An LC, Foldes SS, Alesci NL, Bluhm JH, Bland PC, Davern ME, et al. The impact of smoking-cessation intervention by multiple health professionals. Am J Prev Med 2008;34(1):54–60.

17. Patwardhan PD, Chewing BA. Effectiveness of intervention to implement tobacco cessation counseling in community chain pharmacies. J Am Pharm Assoc (2003) 2012;52(4):507–14.

18. Liu Y, Nevins JC, Carruthers KM, Doucette WR, McDonough RP, Pan X. Osteoporosis risk screening for women in a community pharmacy. J Am Pharm Assoc (2003) 2007;47(4):521–6.

19. Goode JV, Swiger K, Bluml BM. Regional osteoporosis screening, referral, and monitoring program in community pharmacies: findings from Project ImPACT: Osteoporosis. J Am Pharm Assoc (2003) 2004;44(2):152–60.
20. Law AV, Shapiro K. Impact of a community pharmacist-directed clinic in improving screening and awareness of osteoporosis. J Eval Clin Pract 2005;11(3):247–55.

21. MacLaughlin EJ, MacLaughlin AA, Snella KA, Winston TS, Fike DS, Raehl CR. Osteoporosis screening and education in community pharmacies using a team approach. Pharmacotherapy 2005;25(3):379–86.

22. Darin KM, Klepser ME, Klepser DE, Klepser SA, Reeves A, Young M, et al. Pharmacist-provided rapid HIV testing in two community pharmacies. J Am Pharm Assoc (2003) 2015; 55(1):81–8.

23. Calderon Y, Cowan E, Rhee JY, Brusalis C, Leider J. Counselor-based rapid HIV testing in community pharmacies. AIDS Patient Care STDS 2013;27(8):467–73.

24. Weidle PJ, Lecher S, Botts LW, Jones L, Spach DH, Alvarez J, et al. HIV testing in community pharmacies and retail clinics: a model to expand access to screening for HIV infection. J Am Pharm Assoc (2003) 2014;54(5):486–92.

25. Meyerson BE, Ryder PT, von Hippel C, Coy K. We can do more than just sell the test: pharmacist perspectives about over-the-counter rapid HIV tests. AIDS Behav 2013;17(6):2109–13.

26. Agency for Healthcare Research and Quality. Clinical–community linkages. http://www.ahrq.gov/professionals/prevention-chronic-care/improve/community/index.html. Accessed September 20, 2016.

27. Chui MA, Stone JA. Enhancing physician referral and recommendation of pharmacist provided medication therapy management (MTM) services. Community Pharmacy Foundation. http://www.communitypharmacyfoundation.org/resources/grant_docs/CPFGrantDoc_63375.pdf. Accessed September 20, 2016.

28. Keller ME, Kelling SE, Cornelius DC, Oni HA, Bright DR. Enhancing practice efficiency and patient care by sharing electronic health records. Perspect Health Inf Manag 2015; 12(Fall):1b.

29. Wright NC, Looker AC, Saag KG, Curtis JR, Delzell ES, Randall S, et al. The recent prevalence of osteoporosis and low bone mass in the United States based on bone mineral density at the femoral neck or lumbar spine. J Bone Miner Res 2014; 29(11):2520–6.
### Tables

Table 1. Opportunities in the Recommendations of the US Preventive Services Task Force for Community Pharmacists to Conduct Screenings and Provide Recommendations and Referrals for Health Care, 2015

| Recommendation (Activity) | Population                                                                                                                                 |
|---------------------------|---------------------------------------------------------------------------------------------------------------------------------------------|
| **Chronic diseases**      |                                                                                                                                             |
| Blood pressure in adults (screening) | Adults aged 18 years or older                                                                                                                     |
| Cholesterol abnormalities\(^a\) (screening) | Men aged 20–35 years at increased risk for coronary heart disease, all men aged 35 years or older, and women aged 20 years or older at increased risk for coronary heart disease |
| Diabetes mellitus (screening) | Asymptomatic adults with sustained blood pressure (treated or untreated) greater than 135/80 mm Hg                                              |
| **Conditions affecting older adults** |                                                                                                                                             |
| Aspirin for the prevention of cardiovascular disease (preventive medication) | Men aged 45–79 years when the potential benefit due to the reduction in myocardial infarctions outweighs the potential harm of gastrointestinal hemorrhage and women aged 55–79 years when the potential benefit due to the reduction in ischemic strokes outweighs the potential harm of gastrointestinal hemorrhage |
| Fall prevention in older adults (counseling, preventive medication, and other interventions) | Community-dwelling adults aged 65 years or older who are at increased risk for falls                                                                 |
| Osteoporosis (screening) | Women aged 65 years or older and younger women whose fracture risk is equal to or greater than that of a 65-year-old white woman who has no additional risk factors |
| **Healthy behaviors**      |                                                                                                                                             |
| Alcohol misuse screening and behavioral counseling (screening and counseling) | Adults aged 18 years or older                                                                                                                     |
| Depression in adults (screening) | Adults aged 18 years or older                                                                                                                     |
| Folic acid supplementation to prevent neural tube defects (preventive medication) | All women planning or capable of pregnancy                                                                                                        |
| Healthy diet and physical activity counseling to prevent cardiovascular disease (counseling) | Adults who are overweight or obese and have additional cardiovascular disease risk factors                                                        |
| Intimate partner violence (screening) | Women of childbearing age                                                                                                                        |
| Obesity in adults (screening and counseling) | Adults aged 18 years or older                                                                                                                      |
| Tobacco use in adults (counseling and interventions) | Adults aged 18 years or older                                                                                                                      |
| **Infectious diseases**    |                                                                                                                                             |
| Hepatitis C virus infection (screening) | People at high risk for infection and adults born during 1945–1965                                                                         |
| HIV infection (screening)  | People aged 15–65 years, younger adolescents, and older adults at increased risk                                                               |

\(^a\) Four separate age-based and sex-based recommendations have been summarized into this category.
Table 2. Opportunities in the Recommendations of the US Preventive Services Task Force for Community Pharmacists to Provide Education and Referrals for Health Care, 2015

| Recommendation (Activity)                  | Population                                                                 |
|--------------------------------------------|-----------------------------------------------------------------------------|
| **Cancer**                                 |                                                                             |
| BRCA-related cancer in women (screening)   | Women with a family history of breast cancer and who are at low risk for adverse medical effects |
| Breast cancer (preventive medication)      | Women at increased risk for breast cancer and low risk for adverse medical effects |
| Breast cancer (screening)                 | Women aged 40 years or older                                                |
| Cervical cancer (screening)               | Women aged 21–65 years                                                     |
| Colorectal cancer (screening)            | Adults aged 50–75 years                                                     |
| Lung cancer (screening)                  | Adults aged 55–80 years who have a 30 pack-year smoking history and currently smoke or have quit within the past 15 years |
| Skin cancer (counseling)                 | People aged 10–24 years who have fair skin                                  |
| **Conditions affecting older adults**     |                                                                             |
| Abdominal aortic aneurysm (screening)     | Men aged 65–75 years who have ever smoked                                    |
| Fall prevention in older adults (exercise or physical therapy) | Community-dwelling adults aged 65 years or older at increased risk for falls |
| **Infectious diseases**                   |                                                                             |
| Chlamydia (screening)                    | Sexually active women aged 24 years or younger and older women at increased risk for infection |
| Gonorrhea (screening)                    | Sexually active women aged 24 years or younger and older women at increased risk for infection |
| Hepatitis B (screening)                  | People at increased risk                                                    |
| Sexually transmitted infections (counseling) | All sexually active adolescents and adults at increased risk                |
| Syphilis (screening)                     | People at increased risk                                                    |

*The number of packs of cigarettes smoked per day multiplied by the number of years the person has smoked (eg, 1/2 pack per day × 10 years = 5 pack-year history; 2 packs per day × 10 years = 20 pack-year history).*